Co-prescribing Rinvoq (Upadacitinib) with Ergomar (Ergotamine) is Generally Safe
There is no documented pharmacological contraindication to co-prescribing Rinvoq (upadacitinib) with Ergomar (ergotamine), as these medications do not have clinically significant drug-drug interactions based on their distinct mechanisms of action and metabolic pathways.
Pharmacological Rationale
Distinct Metabolic Pathways
Upadacitinib is primarily metabolized by CYP3A4 1, while ergotamine's interactions are primarily related to its vasoconstrictive properties and interactions with other vasoactive medications 2. The FDA label for Rinvoq specifically addresses interactions with CYP3A4 inhibitors and inducers but does not list ergot alkaloids as contraindicated medications 1.
No Direct Interaction Evidence
The perioperative guideline recommends holding ergotamine at least 2 days prior to surgery due to concerns about prolonged vasoconstriction and potential interactions with anesthetics 3. However, this recommendation is specific to the perioperative setting and does not apply to routine outpatient co-administration with JAK inhibitors.
Clinical Considerations
Monitor for Ergotamine-Related Adverse Effects
Ergotamine carries significant cardiovascular risks including:
- Coronary vasospasm and myocardial ischemia 2
- Prolonged vasoconstriction lasting beyond pharmacological duration 3
- Arterial spasm and peripheral ischemia 2
Upadacitinib Safety Profile
While upadacitinib has specific safety concerns including increased risk of:
- Herpes zoster infection 4, 5
- Venous thromboembolism (particularly in high-risk patients) 4, 6
- Hepatic dysfunction and neutropenia (dose-dependent) 5
These risks are independent of ergotamine co-administration.
Practical Management Algorithm
Step 1: Verify the patient requires both medications
- Confirm ergotamine is being used appropriately for acute migraine (not chronic daily use) 2
- Ensure upadacitinib indication is appropriate (rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, etc.) 7, 4
Step 2: Screen for cardiovascular risk factors that would contraindicate ergotamine regardless of upadacitinib use:
- Coronary artery disease
- Uncontrolled hypertension
- Peripheral vascular disease
- History of myocardial infarction 2
Step 3: Assess for upadacitinib-specific contraindications:
- Active serious infections
- History of venous thromboembolism (particularly if multiple risk factors present) 4
- Severe hepatic impairment (Child-Pugh C) 4, 1
- Severe renal impairment (CrCl <30 mL/min requires dose adjustment) 1
Step 4: Educate patient on proper ergotamine use:
- Use only at migraine onset, not prophylactically 2
- Maximum 3 doses in 24 hours 2
- Limit to 2-3 days per week to avoid medication-overuse headaches 2
Important Caveats
Avoid Strong CYP3A4 Inhibitors
If the patient requires a strong CYP3A4 inhibitor (such as clarithromycin or ketoconazole), this creates a more complex situation 1. Clarithromycin is specifically listed as contraindicated with dihydroergotamine 2, and would also increase upadacitinib exposure 1. In this scenario, avoid the triple combination and consider alternative antimigraine therapy.
Consider Alternative Migraine Treatments
Given ergotamine's significant adverse effect profile and multiple contraindications 2, 3, 2, consider whether triptans or other antimigraine medications might be more appropriate, particularly if the patient has cardiovascular risk factors that overlap with upadacitinib's thrombotic concerns 4.
Monitor for Additive Thrombotic Risk
While not a direct drug interaction, patients on upadacitinib already have increased thrombotic risk 4, 6. Ergotamine's vasoconstrictive effects theoretically could compound this risk in susceptible individuals. Exercise particular caution in patients with:
- Age >65 years
- History of thromboembolism
- Multiple cardiovascular risk factors
- Obesity or immobility 4
The combination can be prescribed, but requires careful patient selection and monitoring for cardiovascular and thrombotic complications from both medications independently.